Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising R&D investments and demand for novel cancer therapeutics
3.2.1.2 Technological advancements in gene therapy
3.2.1.3 Increasing incidence of cancer
3.2.1.4 Increasing number of product approvals and launches
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of therapy
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter’s analysis
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive positioning matrix
4.4 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Million)
5.1 Key trends
5.2 Ex-vivo
5.3 In-vivo
Chapter 6 Market Estimates and Forecast, By Therapy, 2021 – 2032 ($ Million)
6.1 Key trends
6.2 Oncolytic virotherapy
6.3 Gene-induced immunotherapy
6.4 Gene transfer
Chapter 7 Market Estimates and Forecast, By Product, 2021 – 2032 ($ Million)
7.1 Key trends
7.2 Viral vectors
7.2.1 Adenoviruses
7.2.2 Lentiviruses
7.2.3 Retrovirus
7.2.4 Adeno associated virus
7.2.5 Herpes simplex virus
7.2.6 Vaccinia virus
7.2.7 Other viral vectors
7.3 Non-viral vectors
7.4 Other products
Chapter 8 Market Estimates and Forecast, By End-use, 2021 – 2032 ($ Million)
8.1 Key trends
8.2 Biopharma companies
8.3 Research institutes
8.4 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Million)
9.1 Key trends, by region
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 Rest of Asia Pacific
9.5 Rest of the World
Chapter 10 Company Profiles
10.1 Abeona Therapeutics Inc.
10.2 Altor Bioscience Inc.
10.3 Asklepios BioPharmaceutical Inc.
10.4 Bluebird bio, Inc.
10.5 Bristol-Myers Squibb Company
10.6 Elevate Bio
10.7 Genelux Corporation
10.8 GlaxoSmithKline Inc.
10.9 Introgen Therapeutics Inc.
10.10 Merck KGaA
10.11 Novartis AG
